Leukemia Clinical Trials in Boston

Showing 1261-1280 of 1,445 trials

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00275028

This phase II trial is studying how well AZD2171 works in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Fallopian Tube CancerPrimary Peritoneal Serous AdenocarcinomaRecurrent Ovarian Epithelial Cancer+2 more

National Cancer Institute (NCI)47 participantsStarted Oct 2005

Boston, Massachusetts, United States

TERMINATEDPhase 3< 1 mile

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881

This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other places in the body. Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium is more effective than erlotinib hydrochloride in treating advanced non-small cell lung cancer.

Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer+1 more

National Cancer Institute (NCI)23 participantsStarted Oct 2008

Scottsdale, Arizona, United States • Fort Smith, Arkansas, United States • Antioch, California, United States +266 more locations

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Leukemia Trials in Other Cities

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Musculoskeletal Effects of Bicarbonate

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Growth Observational Study

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Other Conditions in Boston